ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / NPCE / forecast
CARL (38) SI (44) BWAY (44) CERS (27) ⌘ Pro Terminal →

Neuropace Inc. (NPCE) 12-Month Stock Forecast & Price Target Cone

$12.30 -5.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.16

Neuropace Inc. (NPCE) carries a Roarable Rating of E (Strong Sell) with 21/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (21/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $422.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NPCE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NPCE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Neuropace Inc. (NASDAQ: NPCE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $12.30 (-5.46% 1D, market cap $422.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NPCE ranks #968 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NPCE compare to CARL and SI in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), NPCE carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of 77.2%, and ROIC of -23.0%. By comparison, CARL (Carlsmed Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $408.2M) and SI (Shoulder Innovations Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -16.1%, cap $398.3M). Among the 5-stock peer group, NPCE leads on earnings multiple (N/A) while CERS leads on capital efficiency (-15.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NPCE?
▼

Per NPCE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001528287), Neuropace Inc. generated $100.0M in revenue (+25.1% YoY), -$21.5M in net income, and -$11.3M in free cash flow against $105.6M in total assets and $58.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $12.16 (-1.17%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (21/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510021
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (5)Whales (4)SEC (6)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-16.7% Base Target
$21 Bull$10 Base$8 Bear
📬 FREE NPCE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NPCE)Realized 20D OHLCV Swing Band: ±9.1%
Deterministic 5-Pillar Attribution (21/100 Composite)
🔍 WHY NPCE SCORES 21/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (29% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 77.2% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
29
Grade E$12.68+6.5% Next Q
Q2 (-2Q)
26
Grade E$13.51-3.6% Next Q
Q3 (-1Q)
24
Grade E$13.02-5.5% Next Q
Current
21
Grade E$12.30-11.6% Hist 90D α
Trajectory: E (29) → E (21)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NPCE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NPCE currently carries a cautious 21/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.62) and Max Pain ($12.92) forces dealer call-delta covering toward $20.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NPCE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NPCE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 21%NO 79%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your NPCE Position Size: $10,000

Shares at $12.30: 813.0 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $8.00
$6,504
$-3,496 (-35.0%)
12M Consensus BaseTarget $10.25
$8,333
$-1,667 (-16.7%)
12M Bull Case BreakoutTarget $20.58
$16,732
+$6,732 (+67.3%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$1174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$1969%B
JP MorganUS Large-Cap ResearchSELL$958%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NPCE)

  • ✓Walkthrough of NPCE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NPCE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.22%🛡️ HOLDING TREND SUPPORT
2026-11-03O $13.01H $13.01L $12.30C $12.30VOL 80.9K
RES: $13.15SUP: $11.70SMA50: $13.62SMA200: $14.94
$20.12$17.96$15.79$13.62$11.46RES $13.15SUP $11.70$12.302026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NPCE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NPCE Butterfly Map → + Track NPCE →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +25.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NPCE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NPCE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NPCE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NPCE)

Health Care Rank #968 of 1016 ⚔️ CARL vs NPCE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NPCE vs. CARL, SI, BWAY, CERS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Neuropace Inc. (NPCE) ranks #968 by composite RQD confidence (21/100, grade E) and #466 by equity capitalization ($422.2M). Within this direct 5-issuer industry benchmark cohort, NPCE leads on earnings valuation at N/A trailing P/E, while CERS leads on capital efficiency and profitability with -15.5% ROIC and — gross margin. SI currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with NPCE at 21/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NPCE ACTIVE
Neuropace Inc.
E 21/100 — 77.2% -23.0% -5.46% $422.2M Benchmark Subject
CARL
Carlsmed Inc.
D- 38/100 — 75.3% -35.0% -5.20% $408.2M /carl-vs-npce →
SI
Shoulder Innovations Inc.
D 44/100 — 76.5% -16.1% -6.41% $398.3M /si-vs-npce →
BWAY
BrainsWay Ltd.
D 44/100 — — — -4.78% $455.9M /bway-vs-npce →
CERS
Cerus Corporation
E 27/100 — — -15.5% -6.56% $459.5M /cers-vs-npce →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001528287

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neuropace Inc. (NPCE) reported GAAP revenue of $100.0M (+25.1% vs. FY2024 revenue of $79.9M , and +52.8% cumulative change since FY2023) , GAAP net income of -$21.5M, operating cash flow of -$11.0M, and free cash flow of -$11.3M (+37.9% YoY). On the balance sheet, NPCE closed FY2025 with $105.6M in total assets against $58.9M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $100.0M -$21.5M -$11.0M -$11.3M $105.6M $58.9M
FY2024 (FY) 2024-12-31 $79.9M -$27.1M -$17.9M -$18.3M $94.6M $59.5M
FY2023 (FY) 2023-12-31 $65.4M -$33.0M -$19.7M -$19.7M — —

3. NPCE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NPCE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Neuropace Inc. (NASDAQ: NPCE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $12.30 (-5.46% 1D, market cap $422.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NPCE ranks #968 in composite RQD confidence.

How does NPCE compare to CARL and SI in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), NPCE carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of 77.2%, and ROIC of -23.0%. By comparison, CARL (Carlsmed Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $408.2M) and SI (Shoulder Innovations Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -16.1%, cap $398.3M). Among the 5-stock peer group, NPCE leads on earnings multiple (N/A) while CERS leads on capital efficiency (-15.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NPCE?

Per NPCE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001528287), Neuropace Inc. generated $100.0M in revenue (+25.1% YoY), -$21.5M in net income, and -$11.3M in free cash flow against $105.6M in total assets and $58.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NPCE trading relative to its 50-day, 200-day, and 52-week technical levels?

NPCE last traded at $12.30 (-5.46% on volume of 80,912 shares), positioning the stock -9.69% below its 50-day simple moving average ($13.62) and -17.67% below its 200-day simple moving average ($14.94). Across its 52-week range of $9.22 to $19.60, NPCE sits at the 29.7% percentile with a 14-day RSI of 41.7 (NEUTRAL RANGE) and an implied next-earnings move of ±9.1% ($11.18 to $13.42).

NPCE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is NPCE's 12-month stock price target?

Neuropace Inc. (NPCE) carries a 12-month consensus base price target of $10.25 (-16.7% from $12.30), with a bull-case target of $20.58 and a bear-case floor of $8.

Is NPCE stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates NPCE E (Strong Sell — SELL) with an RQD Confidence score of 21/100.

Direct Sub-Reports: NPCE RQD Cockpit NPCE 12M Forecast NPCE Earnings & Move NPCE Dividends & DRIP NPCE Insiders & 13F NPCE Whale Options NPCE Profit Sankey NPCE News & Why
ROARABLE RATING BRIEF • RQD 21/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

NPCE — Neuropace Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:36:22Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, NPCE carries an RQD Score of 23 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars: Fundamental Cash Engine scores 5/20 (ROIC -23%; FCF yield -2.54%), indicating the business is not currently generating cash returns on invested capital. Whale 13F Flow scores 6/20 (institutional accumulation and options positioning). Insider Conviction scores 3/20 (SEC Form 4 and Congressional PTR cluster flow). Macro Regime Fit scores 3/20 (Beta 1.0; sector sensitivity). Forensic Balance Sheet scores 6/20 (Altman Z 0.2; Piotroski F 5/9; Debt/Equity 3.09). For a prospective investor, the combination of negative returns on capital, negative free cash flow yield, weak forensic balance-sheet readings, and low insider conviction points to a high-risk profile on the rating's own framework. Any upside case would depend on operating improvement that the cited metrics do not yet show, and the rating's verdict is an analytical classification, not a recommendation.

Business

Per the profile, Neuropace Inc. is a NASDAQ-listed issuer in the Health Care sector and Medical/Dental Instruments industry, with a market capitalization of $0.4B. Per the market data, the company reports a gross margin of 77.2%. The source data does not describe specific products, customer segments, or the mechanics of how revenue is generated beyond the sector and industry classification.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$100.0M$-16.3M$-21.5MN/A$-11.3M$21.7M$58.9M
FY 2024$79.9M$-21.7M$-27.1MN/A$-18.3M$13.4M$59.5M
FY 2023$65.4M$-27.2M$-33.0MN/A$-19.7MN/AN/A

Per the SEC financials, revenue rose across the three reported years while operating and net losses narrowed from FY 2023 to FY 2025. Per the market data, operating margin is -16.3% and net margin is -21.5%, with ROIC at -23%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 5/9, with Debt/Equity at 3.09. The balance sheet reflects debt of $58.9M against cash of $21.7M in the most recent reported period.

Recent Catalysts & News Wire Analysis

Per the news wire, a live results call from NeuroPace is scheduled for 1:30 p.m. Pacific on Nov. 12, and a MarketBeat item notes the company is projected to release earnings on Tuesday. Several items report the stock slipping to $12.56 as shares consolidate below resistance, described as an island reversal in one headline. A Stock Traders Daily item and a MarketBeat item cover institutional positioning and brokerage commentary, though the summaries do not contain specific figures. Risk watch items include the negative forensic readings and cash-flow metrics cited in the RQD rating. Per the Butterfly Supply-Chain Graph, there are no proprietary signals. All news items are tagged YELLOW.

Open Questions

  • What are the company's specific products, customers, and revenue drivers, given that the source describes only sector and industry?
  • What are the terms, maturity, and interest cost of the $58.9M in debt, and how does the company plan to fund negative free cash flow?
  • What drove the revenue increase from $65.4M to $100.0M, and what share came from recurring versus one-time sources?
  • Why is EPS reported as N/A across all periods, and what share count underlies the $446.6M market capitalization?
  • What do the pending results-call disclosures on Nov. 12 show for guidance, margins, and cash burn?

NPCE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Neuropace Inc. (NPCE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NPCE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NPCE Bull vs. Bear Conversation Board — What's Your Call at $12.30?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NPCE 🐻 67% BEARISH CONVICTION
1. Pick Your Side on NPCE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $11.45 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is NPCE (E • RQD 23/100) a Buy at $13.01?

Welcome to the NPCE (Neuropace Inc.) Roar Pit. Current RQD Composite is 23/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $10.15 (-22.0%)
Spot @ $13.01

Pump the brakes on NPCE — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NPCE, but look at what you are paying: current EV/EBITDA multiples with 77.2% gross margins. Unless Neuropace Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $16.26 (+25.0%)
Spot @ $13.01

NPCE cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NPCE, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $13.01 (52-wk range $9.22 - $19.60), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%